Chikungunya virus vaccine

Eli Lilly has extended its research collaboration with Purdue University through 2032, investing up to $250 million over the next eight years in what could become the largest industry-academic partnership in the United States.

FDA Commissioner Martin Makary announced an agency-wide rollout of AI tools to assist with scientific reviews across all 11 FDA centers, with full deployment expected by June 30, 2025.

European Medicines Agency has suspended the use of Valneva's IXCHIQ chikungunya vaccine in people over 65 years old following reports of 17 serious adverse events, including two deaths, in elderly patients.

The EMA's Committee for Medicinal Products for Human Use (CHMP) has granted a positive opinion for Vyjuvek (beremagene geperpavec) to treat wounds in patients with dystrophic epidermolysis bullosa of all ages.

The European Medicines Agency (EMA) has recommended eight new products for EU-wide approval, expanding treatment options for various conditions.